

CHOLINESTERASE (CHE)

Diagnostic reagent for the determination of Cholinesterase concentration.

Liquid. Dual Reagents. Store at +2/+8°C. For in Vitro Diagnostic Use. Do not freeze.

Ref No	Pack
MH-112	72 mL

Changes made in the instructions for use are marked as grey.



INTENDED USE

The test is applied for the quantitative determination of cholinesterase in serum or plasma.

TEST SUMMARY AND PROCEDURE ^{1, 2, 3, 4, 5}

Cholinesterases are a group of enzymes preferably splitting choline and thiocholine esters. The names Serum Cholinesterase and Pseudo cholinesterase are also commonly used. The ChE measured in serum and plasma is synthesized in the liver and is determined in diagnosis of liver diseases, nephritic syndrome and intestinal diseases with loss of protein (exudative enteropathy). Strongly decreased values can indicate intoxication by pesticides. Measurement of ChE is also a part of pre-operative diagnostics as ChE is needed for the inactivation of muscle relaxants often used in surgeries.

ChE hydrolyses butyrylthiocholine under release of butyric acid and thiocholine. Thiocholine reduces yellow potassium hexacyanoferrate (III) to colorless potassium hexacyanoferrate (II). The decrease of absorbance is measured at 405 nm.



TEST PARAMETERS

Method : Kinetic
Wavelength : 405 nm
Linearity : 25000 U/L

REAGENT COMPONENTS

Reagent 1:

Pyrophosphate pH 7.6 ≤ 77 mmol/L
Potassium
Hexacyanoferrate (III) ≤ 2.4 mmol/L

Reagent 2:

Butyrylthiocholine ≤ 18 mmol/L

REAGENT PREPARATION

Reagents are ready for use.

REAGENT STABILITY AND STORAGE ⁶

Reagents are stable at +2/+8°C till the expiration date stated on the label which is only for closed vials.

Once opened vials are stable for 30 days at +2/+8°C in optimum conditions. On board stability is strongly related to auto analyzers' cooling specification and carry-over values.

Reagent stability and storage data have been verified by using Clinical and Laboratory Standards Institute (CLSI) EP25-A protocol.

SAMPLE

Serum and heparin plasma are collected according to the standard procedures.

Contact with light must be avoided.
Samples are stable for 15 days at +2/8°C.

REFERENCE INTERVAL (NORMAL VALUES) ⁷

Women	3930 U/L	10800 U/L
Men	4620 U/L	1150 U/L

It is recommended that each laboratory establish its own normal range.

Reference interval has been verified by using CLSI EP28-A3c protocol.

QUALITY CONTROL AND CALIBRATION

Commercially available control material with established values determined by this method may be used. We recommend:

Arcon N (Level I Control) Lyophilized
Ref.No: VT-001

Arcon N (Level I Control) Lyophilized
Ref.No: VT-002

The assay requires the use of an Arcal Auto Calibrator. We recommend:

ARCAL AUTO
Ref.No: VT-003

Calibration Stability: It strongly depends on the application characteristics of in-use auto analyser and capacity of cooling. Calibration stability is 7 days.

Each laboratory should establish its own internal Quality Control scheme and procedures for corrective and preventive action if controls do not recover within the acceptable tolerances.

Quality control is recommended every morning. Calibration is not recommended if QC control values are acceptable. Reagent should be calibrated after lot changes.

PERFORMANCE CHARACTERISTICS

Limit of Detection (LoD): The limit of detection is 40 U/L.

Limit of Quantitation (LoQ) [LoQ values are based on Coefficient of Variation Percentage (CV) % ≤ 20]:⁸50 U/L

LoD and LoQ values have been verified by using CLSI EP17-A protocol.

High Linearity: The method is linear up to 25000 U/L.

For values above high linearity, dilute sample with 0.9% saline, repeat the test and multiply the result by the dilution factor.

Linearity may considerably vary depending on the instrument used.

Precision Studies:⁹

Repeatability (Within Run) (Intra-Assay):

Mean Concentration	SD*	CV%	n
4188 U/L	39.8	0.95	40
5518 U/L	27.4	0.50	40
8805 U/L	44.3	0.50	40

Reproducibility (Run to Run) (Inter-Assay):

Mean Concentration	SD	CV%	n
4082 U/L	49.4	1.21	40
5474 U/L	82.1	1.50	40
8821 U/L	216	2.45	40

*SD: Standard Deviation

Precision Studies data have been verified by using CLSI EP05-A3 protocol.

Method Comparison:^{10, 11}

Correlation with a comparative method is: $r = 0.994$

According to Passing-Bablok Fit:

Slope: 0,948

Intercept: 89

Interference:^{2, 3, 4, 12}

No significant interference was observed for hemoglobin, lipemia, ascorbic acid, bilirubin up to the interferent concentration given.

Ascorbic Acid	: ≤ 30 mg/dL
Bilirubin	: ≤ 45 mg/Dl
Hemoglobin	: ≤ 1000 mg/Dl
Lipemia	: ≤ 1400 mg/dL

The acceptable interference limit is set 10% below the highest interference concentration within ± 10% recovery of the target.

Interferences may affect the results due to medication or endogenous substances.

These performance characteristics have been obtained by using an analyzer. Results may vary if a different instrument or a manual procedure is used.

WARNINGS AND PRECAUTIONS

IVD: For in Vitro Diagnostic use only.

Do not use expired reagents.

Reagents with two different lot numbers should not be interchanged.

For professional use.

Follow Good Laboratory Practice (GLP) guidelines.

CAUTION: Human source samples are processed with this product. All human source samples must be treated as potentially infectious materials and must be handled in accordance with OSHA standards.

Danger

EUH032 :Releases a very toxic gas if contacts with acid.

H317 :May cause allergic skin reaction.

Precaution

P280 :Use protective gloves / clothes / glasses / mask.

P264 :Wash your hands properly after using.

P272 :Contaminated work clothes should not be allowed to be used outside of the workplace.

Intervention

P302+P352 :Wash with plenty of water and soap if it contacts with skin.

- P333+P313 :Seek medical help if it irritates your skin or develops rash.
- P362+P364 :Remove contaminated clothes and wash properly before using.

Disposal

- P501 :Dispose the vials and contents according to the local regulations.







REFERENCES

1. Tietz, N.W., Fundamentals of Clinical Chemistry, p. 940, W.B. Saunders Co., Philadelphia, 1987.
2. Tietz NW. Clinical Guide to Laboratory Test. 2nd ed. Philadelphia, PA: WB Saunders Company; 1995:52.
3. Tietz NW. Clinical Guide to Laboratory Tests. 3rd ed. Philadelphia, PA: WB Saunders Company; 1995:88-91.
4. Tietz NW, ed. Clinical Guide to Laboratory Tests. 3rd ed. Philadelphia: WB Saunders 1995:919.
5. Tietz Fundamentals of Clinical Chemistry. 5th ed. Burtis CA, Ashwood ER, eds. Philadelphia, PA: WB Saunders Company; 2001:605.
6. Clinical and Laboratory Standards Institute (CLSI). Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline. CLSI Document EP25-A. Wayne, PA: CLSI; 2009.
7. Clinical and Laboratory Standards Institute (CLSI). Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline – Third Edition. CLSI Document EP28-A3c. Wayne, PA: CLSI; 2010.
8. Clinical and Laboratory Standards Institute (CLSI). Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline. CLSI Document EP17-A. Wayne, PA: CLSI; Vol. 24 No. 34.
9. Clinical and Laboratory Standards Institute (CLSI). Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline – Third Edition. CLSI Document EP05-A3. Wayne, PA: CLSI; 2014
10. Passing-Bablok W et al. A General Regression Procedure for Method Transformation. J Clin Chem Clin Biochem 1988;26:783-79.
11. Clinical and Laboratory Standards Institute (CLSI). Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline—Second Edition; Approved Guideline. CLSI Document EP09-A2. Wayne, PA: CLSI; Vol. 22 No. 19.
12. Clinical and Laboratory Standards Institute (CLSI). Interference Testing in Clinical Chemistry; Approved Guideline. CLSI Document EP07. Wayne, PA: CLSI; 3rd Edition. CHERIAN G., SOLDIN ST. Clin. Chem. 27/5:748-752 (1981)
13. Young DS. Effects of Drugs on Clinical Laboratory Tests. 3rd ed. Washington: AACC Press; 1990.
14. Tietz NW. Clinical Guide to Laboratory Tests. 3rd ed. Philadelphia, PA: WB Saunders Company; 1995:186-187.
15. Whittaker M. Methods of Enzymatic Analysis. 3rd ed. vol IV, HU Bergmeyer, ed, New York, NY: Academic Press; 1984:52.
16. Moss DW, Henderson AR. Clinical enzymology. In: Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia: W.B Saunders Company; 1999. p. 617-721.
17. Thomas L. Clinical Laboratory Diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft; 1998. p. 89-94
18. Burtis CA, Ashwood ER. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia, PA: WB Saunders Company; 1999:708-709.
19. Clinical and Laboratory Standards Institute (formerly NCCLS). Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline - Second Edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2004. NCCLS Document EP05-A2.
20. Knedel M, Bottger P. A kinetic method for determination of the activity of pseudocholinesterase (acylcholine acylhydrolase. E.C.3.3.3.8). Klin Wochenschr. 1967;45:325-327.



Archem Sağlık Sanayi ve Tic. A.Ş. (With official contract based manufacturing agreement with Validity Sağlık Hiz. Sanayi A.Ş. Company)
Mahmutbey Mah. Halkalı Cad. No:124 Kat:4
Bağcılar/İstanbul/Turkey
Tel: + 90 212 444 08 92
Fax: +90 212 629 98 89
info@archem.com.tr www.archem.com.tr
info@validity.com.tr www.validity.com.tr



SYMBOLS	
IVD	In Vitro Diagnostic Medical Device
LOT	Lot Number
R1	Reagent 1
R2	Reagent 2
GTIN	Global Trade Item Number
REF	Reference Number
GLP	Good Laboratory Practices
FOR USE WITH	Identifies Products to Be Used Together
PRODUCT OF TURKEY	Product of Turkey
	Manufacturer
	Expiration Date
	Temperature Limits
	Consult Instructions for Use
	Caution
	Number of Tests

